Gene therapy for metachromatic leukodystrophy and Gaucher disease

Research output: Contribution to journalArticlepeer-review


Lysosomal storage disorders (LSD(S)) are genetic disorders due to the deficiencies of lysosomal enzymes and resulting in the intracellular accumulation of toxic substrates in different organs, including the Central Nervous System (CNS). Currently, only symptomatic treatments are available for a number of these disorders. In fact, BMT has been carried out for several lysosomal storage diseases, and while normalized levels of enzymatic activity are typically observed in peripheral blood leukocytes after successful BMT, reports have varied concerning improvements in the neuropsychological status of patients with CNS involvement. Therefore, gene therapy might be a route to be pursued for the treatment of these diseases. This review describes possible approaches for gene therapy of two of the most frequent LSD: Metachromatic Leukodystrophy and Gaucher disease.

Original languageEnglish
Pages (from-to)236-241
Number of pages6
JournalMinerva Biotecnologica
Issue number4
Publication statusPublished - Dec 1997


  • Gaucher's disease
  • Gene therapy
  • Metachromatic leukodystrophy

ASJC Scopus subject areas

  • Biotechnology
  • Bioengineering
  • Applied Microbiology and Biotechnology


Dive into the research topics of 'Gene therapy for metachromatic leukodystrophy and Gaucher disease'. Together they form a unique fingerprint.

Cite this